MedTrace Logo

Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study

NCT05109585 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2021-11-05

No results posted yet for this study

Summary

Great expectations to control the pandemic are placed in vaccines against COVID-19. Currently, the four COVID-19 vaccines approved in the European Union. We have designed the study assessing the anti-SARS-CoV-2 IgG antibody titer after vaccination cycle the BNT162b2 vaccine in several time points relating these results to the COVID-19 history and severity of symptoms during the disease and after the first and second vaccine dose

Conditions

  • SARS-CoV2 Infection
  • SARS-CoV2 Antibodies

Interventions

DIAGNOSTIC_TEST

assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule

evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine

DIAGNOSTIC_TEST

assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule

evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine

Sponsors & Collaborators

  • Collegium Medicum w Bydgoszczy

    lead OTHER

Principal Investigators

  • Jacek Kubica, Prof. · Collegium Medicum w Bydgoszczy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-20
Primary Completion
2022-10-12
Completion
2022-12-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05109585 on ClinicalTrials.gov